Aripiprazole in Children and Adolescents: Clinical Experience
- 1 July 2005
- journal article
- other
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 20 (7) , 603-610
Abstract
Despite few supportive data, aripiprazole was being administered to children and adolescents for management of mood instability, aggression, and psychosis. Using a retrospective review ( n = 11) and prospective recruitment ( n = 6), 17 children and adolescents received aripiprazole 5 to 20 mg/day. Only 4 of 16 bipolar and autistic subjects (25%) demonstrated reduced aggression without adverse events, and the symptoms of 2 of 4 psychotic subjects improved. Coadministration of sedative medications (particularly guanfacine or clonidine) and weight < 58 kg increased the risk of adverse events, such as increased lability and aggression. All three children < 8.6 years old, all four children < 34 kg, and all five children receiving α2-agonists developed adverse events prior to clinical efficacy. Age > 11 years, weight > 58 kg, and absence of sedative medications were associated with a 56% (five of nine) success rate. Until larger, prospective studies are completed, caution is advised when considering aripiprazole for smaller children and children receiving sedative medications. ( J Child Neurol 2005;20:603—610).Keywords
This publication has 19 references indexed in Scilit:
- Parent-Defined Target Symptoms Respond to Risperidone in RUPP Autism Study: Customer Approach to Clinical TrialsJournal of the American Academy of Child & Adolescent Psychiatry, 2003
- Aripiprazole: a partial dopamine D2 receptor agonist antipsychoticExpert Opinion on Investigational Drugs, 2003
- Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust PharmacologyNeuropsychopharmacology, 2003
- Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical AntipsychoticsAmerican Journal of Psychiatry, 2003
- A Case Series of Eight Aggressive Young Children Treated with RisperidoneJournal of Child and Adolescent Psychopharmacology, 2002
- Social and neural determinants of aggressive behavior: pharmacotherapeutic targets at serotonin, dopamine and ?-aminobutyric acid systemsPsychopharmacology, 2002
- Risperidone in Children with Autism and Serious Behavioral ProblemsNew England Journal of Medicine, 2002
- Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapineBrain Research, 2001
- Risperidone Treatment for Juvenile Bipolar Disorder: A Retrospective Chart ReviewJournal of the American Academy of Child & Adolescent Psychiatry, 1999
- Neuroleptics and the neuroleptic‐induced deficit syndromeActa Psychiatrica Scandinavica, 1994